Reading BTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BTMD free→
Biote Corp. (BTMD)
NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-15
Intact
$2.25-8.54%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 67% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. Key factors to watch include guidance changes and sector trends, as these could significantly impact BTMD's outlook. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Care Facilities
- Market cap
- $87.46M
- Employees
- —
- IPO date
- 2021-02-12
- Next earnings
- 2026-08-05
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 5 valuation methods, at three horizons. Current price $2.25. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$6.80consensus
Range $4.92 – $7.24
vs price: -67% below
Method agreement — · 5 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-year—
—consensus
Range — – —
vs price: —
Method agreement —
Embeds projected growth. Leans optimistic by design. Upside context.
5-year—
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peersmedium confidence
At $2.25 BTMD trades at 5× p/e, below its 15× p/e peer median. Our $6.80 fair value sits above the price; medium confidence. Not investment advice.
Multiple (P/E)
4.8x
peer 14.5x · own history —
Premium
0.3x peer
Growth the price needs
-67%
our forecast -3%
Our fair value
$6.80
range $4.16 – $7.24
WhyPeer anchor overstates the discount
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensivecheap — quality intact12-month view
What's priced inJustified
The price implies about 67% below a flat-multiple fair value, below our forecast of about -3%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
83rd pctl · Health Care
Earnings quality
robustOver the trailing year it converted 2.09x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
70th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearishEPS revised -63.6% / 30d, n=1for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.22 → $0.08 (-63.6% / 30d). 0 raised, 1 cut, 1 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
Material events
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- strong
- Earnings discipline
- weak
- Margin discipline
- neutral
- Balance sheet
- weak
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$267.
How much price usually moves either way.
On a bad day, this stock has moved -$643.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,143.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- risk change · risk_labelsmall change
risk label changed from 'elevated' to 'high'.
Risk rose. The risk label changed to "high." The sector backdrop remains a headwind. Recent financial performance is strong, and earnings quality is robust.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceQuartersactive 4d
Watch for Biote Corp. revenue growth re-accelerating
Why it matters: If revenue growth speeds up, it could signal a positive shift for the company. This would be important as the healthcare sector is maturing and slowing down.
What confirms / what disproves
Confirms:Biote Corp. reports revenue growth above 10% year over year in the next earnings report.
Disproves:Revenue growth remains below 10% year over year.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for BTMD yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like HCA, THC, and DVA keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting BTMD and other Healthcare names. Worth watching these names for early signals.
- If BTMD raises forward guidance on the next earnings call (currently REAFFIRMED as of 2026-06-02), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If BTMD cuts guidance on the next call (currently REAFFIRMED as of 2026-06-02), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like HCA, THC, and DVA start missing or guiding lower, the Healthcare tailwind helping BTMD and other Healthcare names could fade. Watch these names for early warning.
- If BTMD misses again next quarter like this past one (a solid miss of -18% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-0215d agoItem 5.02
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Bret Christensen as Chief Executive Officer On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026. Such resign…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+2.3 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.